Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for GeoVax Labs Inc. (GOVX : NSDQ)

• Company Description    GeoVax Labs Inc. is a clinical-stage biotechnology company. It engages in developing human vaccines against infectious diseases and cancer using a novel patented Modified Vaccinia Ankara-Virus Like Particle based vaccine platform. GeoVax Labs Inc. is based in ATLANTA, GA. Number of Employees: 11

• Price / Volume Information    Yesterday's Closing Price: $1.39 Daily Weekly Monthly 20 Day Moving Average: 3,690,035 shares Shares Outstanding: 9.45 (millions) Market Capitalization: $13.13 (millions) Beta: 1.88 52 Week High: $7.50 52 Week Low: $0.55 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 55.60% 70.38% 12 Week -22.35% -12.73% Year To Date -61.60% -53.09%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 1900 LAKE PARK DRIVE SUITE 380 - SMYRNA,GA 30080 USA ph: 678-384-7220 fax: 678-384-7281 investor@geovax.com http://www.geovax.com

• General Corporate Information    Officers David A. Dodd - Chief Executive Officer;President Mark W. Reynolds - Chief Financial Officer Randal D. Chase - Director David A. Dodd - Director Dean G. Kollintzas - Director Peer Information GeoVax Labs Inc. (CORR.) GeoVax Labs Inc. (RSPI) GeoVax Labs Inc. (CGXP) GeoVax Labs Inc. (BGEN) GeoVax Labs Inc. (GTBP) GeoVax Labs Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 373678507 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/10/22 Share - Related Items Shares Outstanding: 9.45 Most Recent Split Date: 9.00 (0.05:1) Beta: 1.88 Market Capitalization: $13.13 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/10/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.16 Price/Cash Flow: - Price / Sales: 36.79 EPS Growth vs. Year Ago Period: -17.24% vs. Previous Quarter: 84.82% Sales Growth vs. Year Ago Period: -25.45% vs. Previous Quarter: -50.30% ROE 03/31/22 - -146.19 12/31/21 - -119.05 09/30/21 - -36.51 ROA 03/31/22 - -116.36 12/31/21 - -104.52 09/30/21 - -35.39 Current Ratio 03/31/22 - 4.75 12/31/21 - 2.14 09/30/21 - 54.05 Quick Ratio 03/31/22 - 4.75 12/31/21 - 2.14 09/30/21 - 54.05 Operating Margin 03/31/22 - -5,443.98 12/31/21 - -4,823.64 09/30/21 - -1,305.93 Net Margin 03/31/22 - -5,443.98 12/31/21 - -4,823.64 09/30/21 - -1,305.93 Pre-Tax Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Book Value 03/31/22 - 1.20 12/31/21 - 0.68 09/30/21 - 2.85 Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00 Debt-to-Capital 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00

Powered by Zacks Investment Research ©